Literature DB >> 26260061

Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals.

Dennis D Rasmussen1,2,3, Carrie L Kincaid2,3, Janice C Froehlich4.   

Abstract

BACKGROUND: Prazosin (PRZ; an α1 -adrenergic receptor antagonist) and naltrexone (NTX; a nonspecific opioid receptor antagonist) each decrease alcohol drinking when administered to rats selectively bred for high voluntary alcohol drinking (alcohol-preferring or "P"), and the combination of PRZ + NTX decreases alcohol drinking more effectively than does either drug alone. As drug responsiveness can depend on history of alcohol drinking and dependence, we investigated whether various schedules of PRZ and NTX administration, alone or in combination, are effective in decreasing alcohol drinking in male P rats with a history of protracted voluntary alcohol drinking, dependence, and repeated withdrawals closely resembling human alcoholism.
METHODS: Male P rats became alcohol-dependent during 1 year of ad libitum 24 h/d access to food, water, and 20% alcohol with repetitive temporary alcohol withdrawals. Four sequential studies then addressed effects of oral PRZ (2 mg/kg) and NTX (10 mg/kg), alone or together, on alcohol drinking during: (i) daily alcohol access with daily drug treatment, (ii) intermittent alcohol access with daily drug treatment, (iii) intermittent alcohol access with occasional drug treatment, and (iv) postdeprivation reinstatement of alcohol access.
RESULTS: The combination of PRZ + NTX consistently suppressed alcohol drinking during daily or intermittent alcohol access conditions and when drug treatment was either daily or occasional. PRZ + NTX was consistently more effective than either drug alone. The reduction in alcohol drinking was not due to sedation, motor effects, or malaise.
CONCLUSIONS: Both daily and "as-needed" treatment with PRZ + NTX are highly effective in suppressing daily, intermittent, and postdeprivation alcohol drinking in male P rats with a protracted history of alcohol dependence and repeated withdrawals. This drug combination may be especially effective for treating individuals with long histories of heavy alcohol abuse, dependence, and repeated relapse, as commonly encountered in clinical practice.
Copyright © 2015 by the Research Society on Alcoholism.

Entities:  

Keywords:  Alcohol; Alcoholism Treatment; Naltrexone; Noradrenergic; Opioid; Prazosin

Mesh:

Substances:

Year:  2015        PMID: 26260061      PMCID: PMC4558320          DOI: 10.1111/acer.12828

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  48 in total

Review 1.  The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.

Authors:  Helen M Pettinati; Charles P O'Brien; Amanda R Rabinowitz; Shoshana P Wortman; David W Oslin; Kyle M Kampman; Charles A Dackis
Journal:  J Clin Psychopharmacol       Date:  2006-12       Impact factor: 3.153

2.  The neurobiology of ethanol-opioid interactions in ethanol reinforcement.

Authors:  J C Froehlich
Journal:  Alcohol Clin Exp Res       Date:  1996-11       Impact factor: 3.455

3.  The dopamine β-hydroxylase inhibitor, nepicastat, reduces different alcohol-related behaviors in rats.

Authors:  Giancarlo Colombo; Paola Maccioni; Daniela Vargiolu; Barbara Loi; Carla Lobina; Alessandro Zaru; Mauro A M Carai; Gian Luigi Gessa
Journal:  Alcohol Clin Exp Res       Date:  2014-09       Impact factor: 3.455

4.  Activation of the locus coeruleus noradrenergic system by intracoerulear microinfusion of corticotropin-releasing factor: effects on discharge rate, cortical norepinephrine levels and cortical electroencephalographic activity.

Authors:  A L Curtis; S M Lechner; L A Pavcovich; R J Valentino
Journal:  J Pharmacol Exp Ther       Date:  1997-04       Impact factor: 4.030

5.  Noradrenergic terminal excitability: effects of opioids.

Authors:  S Nakamura; J M Tepper; S J Young; N Ling; P M Groves
Journal:  Neurosci Lett       Date:  1982-05-17       Impact factor: 3.046

6.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors:  Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

7.  Adverse effects of oral naltrexone: analysis of data from two clinical trials.

Authors:  C Oncken; J Van Kirk; H R Kranzler
Journal:  Psychopharmacology (Berl)       Date:  2001-04       Impact factor: 4.530

8.  The α1-adrenergic receptor antagonist, doxazosin, reduces alcohol drinking in alcohol-preferring (P) Rats.

Authors:  Meghan L O'Neil; Lauren E Beckwith; Carrie L Kincaid; Dennis D Rasmussen
Journal:  Alcohol Clin Exp Res       Date:  2012-07-03       Impact factor: 3.455

9.  Time-dependent quantifiable withdrawal from ethanol in the rat: effect of method of dependence induction.

Authors:  D J Macey; G Schulteis; S C Heinrichs; G F Koob
Journal:  Alcohol       Date:  1996 Mar-Apr       Impact factor: 2.405

Review 10.  A role for brain stress systems in addiction.

Authors:  George F Koob
Journal:  Neuron       Date:  2008-07-10       Impact factor: 17.173

View more
  9 in total

1.  Evaluation of the effect of doxasozin and zonisamide on voluntary ethanol intake in mice that experienced chronic intermittent ethanol exposure and stress.

Authors:  Marcelo F Lopez; Sarah E Reasons; Benjamin A Carper; Tracy L Nolen; Rick L Williams; Howard C Becker
Journal:  Alcohol       Date:  2020-07-24       Impact factor: 2.405

Review 2.  A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction.

Authors:  R L Bell; S Hauser; Z A Rodd; T Liang; Y Sari; J McClintick; S Rahman; E A Engleman
Journal:  Int Rev Neurobiol       Date:  2016-03-21       Impact factor: 3.230

3.  Combining Varenicline (Chantix) with Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in a Rodent Model of Alcoholism.

Authors:  Janice C Froehlich; Stephen M Fischer; Julian E Dilley; Emily R Nicholson; Teal N Smith; Nick J Filosa; Logan C Rademacher
Journal:  Alcohol Clin Exp Res       Date:  2016-07-29       Impact factor: 3.455

Review 4.  Rat animal models for screening medications to treat alcohol use disorders.

Authors:  Richard L Bell; Sheketha R Hauser; Tiebing Liang; Youssef Sari; Antoniette Maldonado-Devincci; Zachary A Rodd
Journal:  Neuropharmacology       Date:  2017-02-16       Impact factor: 5.250

5.  Co-Administration of Low-Dose Naltrexone and Bupropion Reduces Alcohol Drinking in Alcohol-Preferring (P) Rats.

Authors:  Emily R Nicholson; Julian E Dilley; Janice C Froehlich
Journal:  Alcohol Clin Exp Res       Date:  2018-01-22       Impact factor: 3.455

6.  Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder.

Authors:  Tracy L Simpson; Andrew J Saxon; Cynthia Stappenbeck; Carol A Malte; Robert Lyons; Dana Tell; Steven P Millard; Murray Raskind
Journal:  Am J Psychiatry       Date:  2018-08-29       Impact factor: 18.112

7.  A Combination of Naltrexone + Varenicline Retards the Expression of a Genetic Predisposition Toward High Alcohol Drinking.

Authors:  Janice C Froehlich; Stephen M Fischer; Emily R Nicholson; Julian E Dilley; Nicholas J Filosa; Teal N Smith; Logan C Rademacher
Journal:  Alcohol Clin Exp Res       Date:  2017-02-09       Impact factor: 3.455

Review 8.  Influence of stress associated with chronic alcohol exposure on drinking.

Authors:  Howard C Becker
Journal:  Neuropharmacology       Date:  2017-04-19       Impact factor: 5.250

9.  Acute Hypophagia and Changes in c-Fos Immunoreactivity in Adolescent Rats Treated with Low Doses of Oxytocin and Naltrexone.

Authors:  Mitchell A Head; Laura K McColl; Anica Klockars; Allen S Levine; Pawel K Olszewski
Journal:  J Clin Med       Date:  2021-12-23       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.